Yang TTC - Search Results

1

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.

Miao YR, Thakkar KN, Qian J, Kariolis MS, Huang W, Nandagopal S, Yang TTC, Diep AN, Cherf GM, Xu Y, Moon EJ, Xiao Y, Alemany H, Li T, Yu W, Wei B, Rankin EB, Giaccia AJ. Miao YR, et al. Among authors: yang ttc. Clin Cancer Res. 2021 Aug 1;27(15):4435-4448. doi: 10.1158/1078-0432.CCR-20-0482. Epub 2021 May 19. Clin Cancer Res. 2021. PMID: 34011561 Free PMC article.

2

Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma.

Miao YR, Thakkar K, Cenik C, Jiang D, Mizuno K, Jia C, Li CG, Zhao H, Diep A, Xu Y, Zhang XE, Yang TTC, Liedtke M, Abidi P, Leung WS, Koong AC, Giaccia AJ. Miao YR, et al. Among authors: yang ttc. J Exp Med. 2022 Sep 5;219(9):e20220214. doi: 10.1084/jem.20220214. Epub 2022 Jul 26. J Exp Med. 2022. PMID: 35881112 Free PMC article.

3

Preclinical efficacy and toxicity studies of a highly specific chimeric anti-CD47 antibody.

Xu Z, Gao J, Yao J, Yang T, Wang D, Dai C, Ding Y. Xu Z, et al. FEBS Open Bio. 2021 Mar;11(3):813-825. doi: 10.1002/2211-5463.13084. Epub 2021 Feb 22. FEBS Open Bio. 2021. PMID: 33449453 Free PMC article.

4

Development of a fully human anti-GITR antibody with potent antitumor activity using H2L2 mice.

Tong Q, Liu H, Qi Q, Dai C, Yang T, Qian F. Tong Q, et al. FEBS Open Bio. 2022 Aug;12(8):1542-1557. doi: 10.1002/2211-5463.13451. Epub 2022 Jun 21. FEBS Open Bio. 2022. PMID: 35674216 Free PMC article.

5

Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor.

Liu J, Wang G, Liu L, Wu R, Wu Y, Fang C, Zhou X, Jiao J, Gu Y, Zhou H, Xie Z, Sun Z, Chen D, Dai K, Wang D, Tang W, Yang TTC. Liu J, et al. Among authors: yang ttc. Sci Rep. 2019 Nov 28;9(1):17830. doi: 10.1038/s41598-019-54231-w. Sci Rep. 2019. PMID: 31780710 Free PMC article.

6

Generation and characterization of a high-affinity chimeric anti-OX40 antibody with potent antitumor activity.

Yang Y, Chai X, Xin W, Wang D, Dai C, Qian F, Yang T. Yang Y, et al. FEBS Lett. 2021 Jun;595(11):1587-1603. doi: 10.1002/1873-3468.14079. Epub 2021 Apr 28. FEBS Lett. 2021. PMID: 33792041 Free article.

7

Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates.

Gao Y, Yang T, Liu H, Song N, Dai C, Ding Y. Gao Y, et al. FEBS Open Bio. 2022 Dec;12(12):2166-2178. doi: 10.1002/2211-5463.13494. Epub 2022 Oct 9. FEBS Open Bio. 2022. PMID: 36176235 Free PMC article.

8

Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.

Jiang M, Yang F, Jiang Y, Cheng L, Han J, Yi J, Zuo B, Huang L, Ma Z, Li T, Cao LJ, Xia Z, Bai X, Jia C, Yang TTC, Esmon NL, Ruan C, Xia L, Esmon CT, Han Y, Wu D, Xu J. Jiang M, et al. Among authors: yang ttc. Blood. 2023 Sep 21;142(12):1071-1081. doi: 10.1182/blood.2023020005. Blood. 2023. PMID: 37294924 Free article.

9

Characterization of 405B8H3(D-E), a newly engineered high affinity chimeric LAG-3 antibody with potent antitumor activity.

Lan X, Yang TTC, Wang Y, Qu B, Rong S, Song N. Lan X, et al. Among authors: yang ttc. FEBS Open Bio. 2023 Jul;13(7):1253-1265. doi: 10.1002/2211-5463.13648. Epub 2023 Jun 11. FEBS Open Bio. 2023. PMID: 37302810 Free PMC article.

10

[No title available]

[No authors listed] [No authors listed] PMID: 35108846

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters